mRNA 1010
Alternative Names: mRNA-1010; Quadrivalent seasonal influenza mRNA vaccine - Moderna; Seasonal influenza vaccine - Moderna TherapeuticsLatest Information Update: 30 Sep 2024
At a glance
- Originator Moderna Therapeutics
- Class Influenza virus vaccines; RNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Influenza virus infections
Most Recent Events
- 19 Sep 2024 Moderna Therapeutics plans a phase III trial for Influenza virus infection (Prevention) in Belgium, Bulgaria, Canada, Estonia, Finland, Georgia, Germany, South Korea, Taiwan, United Kingdom and USA (IM, Injection) (NCT06602024)
- 12 Sep 2024 Moderna Therapeutics plans a phase III confirmatory efficacy trial for Influenza virus infections (Prevention) in late 2024
- 24 Jun 2024 Moderna Therapeutics completes a phase III IGNITE P303 trial for Influenza virus infections (Prevention) in USA (IM) (NCT05827978)